Last reviewed · How we verify
NCT03515720
Neuroprolotherapy With Physical Therapy for Treatment of Patellar Chondromalacia
NA trial testing Prolotherapy in Chondromalacia Patellae in 50 participants. Completed in 1 March 2020.
20 September 2019
Quick facts
| Lead sponsor | Instituto Mexicano del Seguro Social |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 1 November 2018 |
| Primary completion | 20 September 2019 |
| Estimated completion | 1 March 2020 |
| Sites | 1 location across Mexico |
Drugs / interventions tested
- Prolotherapy — full drug profile →
Conditions studied
- Chondromalacia Patellae — all drugs for Chondromalacia Patellae →
Sponsor
Instituto Mexicano del Seguro Social — full company profile →
Who can join
Adults 25 to 70, any sex, with Chondromalacia Patellae. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patellar chondromalacia is the degeneration of articular cartilage located on the posterior face of the patella and may suggest the onset of an osteoarthrosis. It predominates in sedentary people who overload the joint, as well as people with insufficiency in the extensor muscles of the knee. It is often seen between 30 and 40 years. Conservative management is the main treatment option and surgical intervention is considered as a last option in a small number of patients. A new treatment option is neuroprolotherapy where the approach is directed at the subcutaneous nerves as the source of pathology, which can lead to neurogenic inflammation and pain.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The Benefit of Perineural Injection Treatment with Dextrose for Treatment of Chondromalacia Patella in Participants Receiving Home Physical Therapy: A Pilot Randomized Clinical Trial.
García-Triana SA, Toro-Sashida MF, Larios-González XV, Fuentes-Orozco C, et al · · 2021 · cited 7× · PMID 33217236 · DOI 10.1089/acm.2020.0287
Verify or expand the search:
- PubMed search for NCT03515720
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Prolotherapy
Trials testing the same drug.
- NCT07399145 — Comparison of Prolotherapy and Rehabilitation Treatments in Low Back Pain (CPRTLBP) · NA · completed
- NCT07355712 — Combined Effect of Prolotherapy and Personalized Physical Activity on Knee Osteoarthritis Progression · NA · completed
- NCT06700746 — Efficacy of Dextrose Prolotherapy Compare With ESWT in the Treatment of Chronic Rotator Cuff Tendinopathy · NA · completed
- NCT06161038 — Precision Medicine for Nociception, Sngception and Proprioception. · NA · recruiting
- NCT06712329 — Chronic Plantar Fasciitis: Which is More Effective? Prolotherapy/Extracorporeal Shock Wave Therapy? · NA · completed
Other Instituto Mexicano del Seguro Social trials
Trials by the same sponsor.
- NCT07536009 — "Effectiveness of a Telerehabilitation Program Versus a Conventional Rehabilitation Program in Patients With Subacromial · NA · not yet recruiting
- NCT06632184 — Peritoneal Lavage Using Saline or Saline With Ondansetron for Pain Control After Laparoscopic Cholecystectomy · Phase 4 · active not recruiting
- NCT07073846 — Effect of Lidocaine-Dexmedetomidine on Pain, Inflammation, and Oxidative Stress After Bariatric Surgery. · Phase 4 · recruiting
- NCT07406971 — Safety of Transmucosal Capsaicin Sphenopalatine Ganglion Stimulation in Acute Ischemic Stroke · Phase 2 · recruiting
- NCT07134504 — Primary Prostatic Lymphoma on a 66 Year-old Male in Mexico. · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03515720 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Instituto Mexicano del Seguro Social
- Last refreshed: 3 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03515720.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing